RSLS•benzinga•
Reshape Lifesciences's Return On Capital Employed Overview
Summary
Benzinga Pro data, Reshape Lifesciences (NASDAQ:RSLS) reported Q2 sales of $2.89 million. Earnings fell to a loss of $9.58 million, resulting in a 16.57% decrease from last quarter.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on September 9, 2022 by benzinga